Search results for: Jorge Mestre-Ferrandiz
Filter search results
Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
22 January 2019
…Report, London: Office of Health Economics Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., 2018. Paying for Cures: Perspectives on Solutions to the “Affordability Issue”. Value in…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…and affordability in the US health care system. Journal of Comparative Effectiveness Research, 7(1), pp.15–28. DOI. RePEc. Schaffer, S.K., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., 2018. Paying…
Quality of Life and Rare Disease: Lessons from Spinal Muscular Atrophy
2 April 2019
…RePEc. Berdud, M., Drummond, M.F., and Towse, A., 2018. Establishing a Reasonable Price for an Orphan Drug. OHE Research Paper. RePEc. Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
…Cole, A., Towse, A. and Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper . OHE Briefing, London: Office of Health Economics. Related research Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and…
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
…London: Office of Health Economics. Available at: https://www.ohe.org/publications/who-technical-report-pricing-cancer-medicines-missing-central-role-hta-and-value Danzon, Towse and Mestre-Ferrandiz (2015). Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context” Health Econ. 24: 294–301. See OHE blog at https://www.ohe.org/news/pricing-variations-within-and-across-countries-gauging-efficiency …
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
…an expanded cost-effectiveness analysis. Value Health, 20(2), pp. 213-16. Garrison L, Mestre-Ferrandiz J, Zamora B. The value of knowing and knowing the value: improving the health technology assessment of complementary diagnostics. White paper. Office of…
Indication-Based Pricing: Are We All Onboard?
12 May 2020
…(2018). Value Assessment of Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/multi-indication-pricing-mip-practical-solutions-and-steps-move-forward# Mestre-Ferrandiz,J., Towse, A., Dellamano, R., and…
The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’
3 December 2020
…Merlin T, Mestre-Ferrandiz J, Oortwijn W, Oosterwijk C, Tunis S, Zamora B. 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into…
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
…3 Mar. 2021]. Kourouklis, D., 2021. Public subsidies for R&D and public sector pharmaceutical innovation. Applied Economics, pp.1–19. 10.1080/00036846.2021.1885614. Mestre-Ferrandiz, J., Sussex, J. and Towse, A., 2012. The R&D Cost…